LLY

992.2

+2.54%↑

JNJ

225.55

+0.2%↑

ABBV

206.52

-0.05%↓

UNH

361.4

-2.18%↓

AZN

184.31

+1.95%↑

LLY

992.2

+2.54%↑

JNJ

225.55

+0.2%↑

ABBV

206.52

-0.05%↓

UNH

361.4

-2.18%↓

AZN

184.31

+1.95%↑

LLY

992.2

+2.54%↑

JNJ

225.55

+0.2%↑

ABBV

206.52

-0.05%↓

UNH

361.4

-2.18%↓

AZN

184.31

+1.95%↑

LLY

992.2

+2.54%↑

JNJ

225.55

+0.2%↑

ABBV

206.52

-0.05%↓

UNH

361.4

-2.18%↓

AZN

184.31

+1.95%↑

LLY

992.2

+2.54%↑

JNJ

225.55

+0.2%↑

ABBV

206.52

-0.05%↓

UNH

361.4

-2.18%↓

AZN

184.31

+1.95%↑

Search

Thermo Fisher Scientific Inc

Chiusa

SettoreSettore sanitario

472.43 2.13

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

459.78

Massimo

468.84

Metriche Chiave

By Trading Economics

Entrata

-314M

1.7B

Vendite

-1.2B

11B

P/E

Media del settore

25.772

49.8

EPS

5.44

Rendimento da dividendi

0.38

Margine di Profitto

15.048

Dipendenti

125,000

EBITDA

-905M

2.3B

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+34.17% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

0.38%

2.25%

Utili prossimi

22 lug 2026

Prossima data del Dividendo

14 lug 2026

Prossima data del' Ex Dividendo

12 giu 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-24B

172B

Apertura precedente

470.3

Chiusura precedente

472.43

Notizie sul Sentiment di mercato

By Acuity

24%

76%

85 / 347 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

Thermo Fisher Scientific Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

23 apr 2026, 13:56 UTC

Utili

Thermo Fisher Profit Up, Warns of Inflation from Iran War -- Update

23 apr 2026, 10:28 UTC

Utili

Thermo Fisher Posts Higher 1Q Profit, Revenue

29 gen 2026, 11:34 UTC

Utili

Thermo Fisher 4Q Profit Rises as Biopharma Spending Rebounds

29 ott 2025, 10:51 UTC

Acquisizioni, Fusioni, Takeovers

Thermo Fisher Scientific Agrees to Buy Clario Holdings for $8.88 billion

23 ott 2025, 20:49 UTC

Utili

Correction to Thermo Fisher Article on Oct. 22

22 ott 2025, 10:28 UTC

Utili

Thermo Fisher 3Q Revenue Rises, Boosted by Life Sciences Business

23 apr 2026, 10:01 UTC

Utili

Thermo Fisher 1Q Organic Revenue Rose 1% >TMO

23 apr 2026, 10:01 UTC

Utili

Thermo Fisher: Well Positioned to Deliver Strong Year >TMO

23 apr 2026, 10:00 UTC

Utili

Thermo Fisher 1Q Net $1.65B >TMO

23 apr 2026, 10:00 UTC

Utili

Thermo Fisher 1Q Adj EPS $5.44 >TMO

23 apr 2026, 10:00 UTC

Utili

Thermo Fisher 1Q EPS $4.43 >TMO

23 apr 2026, 10:00 UTC

Utili

Thermo Fisher 1Q Rev $11.01B >TMO

24 mar 2026, 12:04 UTC

Acquisizioni, Fusioni, Takeovers

Thermo Fisher Completes Acquisition of Clario Holdings for $8.875 Billion >TMO

24 mar 2026, 12:00 UTC

Acquisizioni, Fusioni, Takeovers

Thermo Fisher Scientific Completes Acquisition Of Clario Holdings, Inc. >TMO

29 gen 2026, 11:01 UTC

Utili

Thermo Fisher 4Q Organic Revenue Rose 3% >TMO

29 gen 2026, 11:00 UTC

Utili

Thermo Fisher: Entering 2026 From Position of Strength >TMO

29 gen 2026, 11:00 UTC

Utili

Thermo Fisher 4Q Net $1.96B >TMO

29 gen 2026, 11:00 UTC

Utili

Thermo Fisher 4Q Rev $12.22B >TMO

29 gen 2026, 11:00 UTC

Utili

Thermo Fisher 4Q EPS $5.21 >TMO

29 gen 2026, 11:00 UTC

Utili

Thermo Fisher 4Q Adj EPS $6.57 >TMO

29 ott 2025, 10:06 UTC

Acquisizioni, Fusioni, Takeovers

Thermo Fisher: Clario Provides Endpoint Data Solutions for Clinical Trials >TMO

29 ott 2025, 10:05 UTC

Acquisizioni, Fusioni, Takeovers

Thermo Fisher: Claro Deal Includes Potential Additional Earnout, Other Payments >TMO

29 ott 2025, 10:05 UTC

Acquisizioni, Fusioni, Takeovers

Thermo Fisher to Buy Clario From Group Led by Astorg and Nordic Cap, Novo Holding, Cinven >TMO

29 ott 2025, 10:04 UTC

Acquisizioni, Fusioni, Takeovers

Thermo Fisher Scientific to Pay $8.875 Billion at Closing for Clario Holdings >TMO

29 ott 2025, 10:00 UTC

Acquisizioni, Fusioni, Takeovers

Thermo Fisher Scientific to Acquire Clario Holdings >TMO

22 ott 2025, 10:01 UTC

Utili

Thermo Fisher 3Q Organic Revenue Rose 3% >TMO

22 ott 2025, 10:00 UTC

Utili

Thermo Fisher: In Great Position to Deliver on 2025 Objectives >TMO

22 ott 2025, 10:00 UTC

Utili

Thermo Fisher 3Q Adj EPS $5.79 >TMO

22 ott 2025, 10:00 UTC

Utili

Thermo Fisher 3Q Rev $11.12B >TMO

22 ott 2025, 10:00 UTC

Utili

Thermo Fisher 3Q Net $1.62B >TMO

Confronto tra pari

Modifica del prezzo

Thermo Fisher Scientific Inc Previsione

Obiettivo di Prezzo

By TipRanks

34.17% in crescita

Previsioni per 12 mesi

Media 620.69 USD  34.17%

Alto 685 USD

Basso 560 USD

Basato su 15 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Thermo Fisher Scientific Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

15 ratings

14

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

406.5 / 417.79Supporto e resistenza

A breve termine

Bearish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Strong Bearish Evidence

Sentiment

By Acuity

85 / 347 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. It has a collaboration agreement with Mainz Biomed N.V. for the development of colorectal cancer screening product. Thermo Fisher Scientific Inc. was founded in 1956 and is headquar
help-icon Live chat